Introduction
The use of high-dose chemotherapy and/or radiotherapy, as well as the need for immunosuppressive drugs as prophylaxis or therapy of GvHD, represents the cause of the onset of many complications following haematopoietic SCT (HSCT). Early complications can be defined as those occurring within 100 days after transplant. During this period, both epithelial and endothelial cells suffer from drug-related toxicity. In particular, chemotherapy-related mucosal damage of the gastrointestinal tract is the cause of symptoms similar to the ones that occur after normal courses of chemotherapy, and include oral mucositis, nausea, vomiting and diarrhoea. Urinal tract epithelium toxicity represents one pathogenic mechanism for the onset of haemorrhagic cystitis (HC). Endothelial damage represents the pathogenetic basis for very different clinical features such as veno-occlusive disease (VOD), thrombotic microangiopathic (TAM) anaemia or engraftment syndrome. In this report, we will focus on the most frequent and closely transplant-related early complications.
Vascular origin-related complications
The endothelial damage that is directly caused by conditioning regimen toxicity or that is indirectly caused by the production of cytokines may lead to various complications whose clinical features could depend on the involved district or on the grade and type of general distribution.
Veno-occlusive disease. Veno-occlusive disease represents a frequent complication during the first weeks after HSCT. It is characterized by the obstruction of small intrahepatic venules and is caused by an initial injury of the sinusoid endothelial cells consequent to the conditioning regimen drug toxicity. This obstruction may damage zone 3 of the liver acinus. This area is rich in cytochrome P-450, which represents the main enzymatic system for the clearance of the conditioning regimen drug metabolites. However, as hepatic venule involvement is not always observed in all patients suffering from this complication, the term 'sinusoidal obstruction syndrome' has been proposed. 1 The reported incidence in paediatric patients ranges between 27 and 40%. 2, 3 The variability of the incidence mostly depends on the type of conditioning regimen, and many conditions have been identified as risk factors for developing VOD. They are described in Table 1 . [4] [5] [6] The onset of VOD most often occurs within the first 30 days from HSCT, and symptoms are related to the decrease in hepatic flow, which leads to hepatomegaly, portal hypertension and ascites. 7 Other clinical features include jaundice, right upper quadrant pain and weight gain. VOD may be associated with multiorgan failure and may show thrombocytopenia and refractoriness to platelet transfusions, pulmonary involvement (pulmonary infiltrates and pleural effusion), symptoms of central nervous system failure (encephalopathy and coma) and renal and cardiac failure.
Diagnosis relies on clinical criteria and may be confirmed by complimentary studies. Tables 2 and 3 show the clinical criteria according to the modified Seattle criteria and the staging of the disease. Complementary studies include US scan showing attenuated or reversed portal flow, ascites, hepatomegaly and gallbladder wall thickening. Biological markers may also help to confirm the diagnosis. They include a decrease in anticoagulant levels (such as antithrombin III, proteins C and S) and an increase in the levels of plasminogen activator inhibitor-I and type IIIC aminopeptides. [8] [9] [10] [11] Transjugular liver biopsy may show concentric or eccentric small intrahepatic venule lumen narrowing, sinusoidal fibrosis and/or hepatocyte necrosis. Measuring the hepatic venous pressure gradient adds specificity to the diagnosis. Differential diagnosis must rule out acute GvHD, sepsis (cholangitis lenta) and drug toxicity. According to the literature, overall mortality ranges between 20 and 50%.
Bimodal presentation of the disease, high levels of transaminases, portal vein thrombosis, doubling of serum creatinine and decreased oxygen saturation have been found to correlate with poor prognosis.
Early intervention with defibrotide (DF; 10 mg/kg q 6 h) proved to be effective in treating a large series of patients 12 affected with high-risk VOD. Evaluation of the prophylactic use of DF in children is the main aim of an ongoing prospective trial of the EBMT Paediatric Diseases Working Party.
Although early treatment with recombinant human tissue plasminogen activator seems to be effective, further studies will be necessary to determine its safety as well as the optimal dosing regimen.
Thrombotic microangiopathy. Thrombotic microangiopathy represents one of the most severe vascular damagerelated post transplant complications. The risk factors that are associated with the onset of the disease include the use of CYA or tacrolimus, female gender, TBI, unrelated or haploidentical donor, GvHD and infections. The reported incidence in retrospective studies is 4-13%, but it may actually be higher due to the increasing number of high-risk transplants that are performed. The variety of clinical forms makes diagnosis and treatment difficult. Clinical signs of TAM include haemolytic anaemia, thrombocytopenia and renal and/or central nervous system impairment. TAM must be suspected when a drop in red blood cells and platelet count occurs after primary engraftment. 13 According to an International Working Group consensus, diagnosis of TAM requires the fulfilment of all criteria shown in Table 4. 14 The grading of TAM is shown in Table 5 . Treatment of TAM includes the following:
Replacing CYA or tacrolimus with other immunosuppressive drugs. Performing plasmapheresis. Providing supportive treatment.
The efficacy of plasmapheresis has never been proved and its role remains controversial. The promising role of DF needs to be confirmed by prospective studies.
Children usually have a better outcome than adults. According to various authors, the risk factors that are related to worse outcome are early onset, use of CSA or tacrolimus, kidney or central nervous system involvement, the use of unrelated or haploidentical donors and high TAM index. 15, 16 Engraftment syndrome. The onset of this syndrome may occur 1 or 2 days before the neutrophil count in peripheral blood increases. The stimulus of endogenous cytokines, which can be increased by exogenous G-CSF, may lead to a concentration of neutrophils in pulmonary lesions that may be caused by the toxicity of the conditioning regimen. Clinical symptoms may occur with an incidence ranging between 7 and 59% depending on different diagnostic criteria. They include fever not related to infection, respiratory involvement with pulmonary infiltrates or hypoxia and skin rash. More generalized involvement may lead to weight gain or multiorgan dysfunction. Autologous SCT, non-haematological diseases, high cell dosage and administration of G-CSF represent the main risk factors associated with the onset of the disease. Treatment consists of steroid administration-2 mg/kg/day for a few days followed by tapering. This leads to the resolution of symptoms, especially when administered early. 17 
Haemorrhagic cystitis
Haemorrhagic cystitis represents a common cause of morbidity after HSCT. It may occur early (within 72 h) following transplant, or later, after the first month. It can be caused by the toxic effects of some conditioning regimen agents, or it may represent the effect of a viral infection.
Early-onset HC is mostly related to mucosal damage caused by the catabolites of chemotherapy drugs such as CY, BU and etoposide. Late-onset HC is mostly caused by viral infection and it is mainly associated with human poliomavirus type BK or JC or adenovirus. 18 Risk factors for the onset of HC in children are age o8 years, unrelated donor SCT and male gender. 19, 20 High level of BK viruria represents a risk factor for BK virusrelated HC. 21 A high number of copies of BK in the blood generally anticipates the onset of clinical symptoms; therefore, BK viraemia represents an important marker in clinical practice.
The incidence of this complication ranges between 1 and 25%, if all prevention treatments are implemented. They include a conditioning regimen associated with hyperhydration (3000 ml/m 2 /day) to maintain a urinary output of 100 ml/h and the use of Mesna. Clinical symptoms include microscopic to gross haematuria and dysuria without infections or bleeding diathesis. Table 6 shows the grading of the disease according to the severity of clinical symptoms. 22 Treatment includes general intervention such as hyperhydration and platelet support. In case of vescical clots, bladder irrigation is indicated with or without GM-CSF or prostaglandin whose efficacy has never been demonstrated. In advanced cases, hyperbaric oxygen administration or surgery may be useful. The use of cidofovir for BK virusrelated HC seems encouraging, but further studies are needed to confirm its real efficacy.
